A DAILY pill for the most common form of bladder cancer has been given the green light for NHS use. Erdafitinib, which blocks ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use. The ...

A new pill given the green light for NHS use offers "new hope" to those living with bladder cancer. The drug, called ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

New bladder cancer treatment rolled out by NHS - Hundreds will benefit after the first targeted treatment for the most common ...

The drug, recommended by NICE, works by blocking certain proteins to slow down or stop the growth of cancer cells ...

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use ...

“We hope this is just the start of new hope for those with bladder cancer and their families,” she said. The list price for erdafitinib is £12,750 per 28-day cycle, excluding VAT. The company ...